Gyros this week announced a partnership with EMD Millipore to develop, manufacture, and commercialize immunoassay kits for the Gyrolab platform.
The new kits will take advantage of the capabilities of Gyros' microfluidic technology, which, according to the company, requires smaller sample and reagent volumes and offers increased dynamic range and reduced cross-talk and matrix interference compared to traditional ELISAs.
“We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” Jehangir Mistry, general manager, Multiplex & Immunoassays at EMD Millipore, said in a statement.
Financial and other terms of the agreement were not disclosed.